A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Carcinoma, Non-Small-Cell Lung · Gastric Cancer · Gastroesophageal Junction Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Dec 2024, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 136 (final count)
- Started
- Sep 28, 2021
- Main results expected
- Dec 4, 2024
- Fully finished
- Aug 12, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)
Measured over: From time of Informed Consent to 90 days post last dose of study intervention
Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol
Measured over: From the first patient until the end of the dose escalation period; approximately 18 months.
Preliminary anti-tumour activity of AZD7789
Measured over: From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-12-04, no fading
Raw record changes
- none yet
Trial ID NCT04931654 · record last updated 2025-10-09 · checked 2026-11-09 15:47 UTC